A scientist works in GlaxoSmithKline's plant in Singapore December 16, 2005. The European Medicines Agency has recommended conditional approval of GlaxoSmithKline Plc's new breast cancer pill Tykerb, Europe's biggest drugmaker said on Friday. (Luis Enrique Ascui/Reuters)LONDON (Reuters) - GlaxoSmithKline Plc announced furtherclinical trial results on Sunday underlining the ability of adrug combination including its product Tykerb to fight breastcancer that has spread to the brain.
An extension to an earlier Phase II study involving 49patients showed 20 percent of those receiving a mix of Tykerband Roche's Xeloda experienced at least a 50 percent volumereduction in measurable brain metastases.
The finding is significant because up to a third of womenwith HER2-positive metastatic breast cancer may develop brainmetastases, which occur when cancer spreads from its originalsite.
The results were presented at the San Antonio Breast CancerSymposium in San Antonio, Texas.
Tykerb, a once-daily pill, was approved by U.S. regulatorsin March and won a conditional green light from the EuropeanMedicines Agency on Friday.
It is recommended as a treatment, in combination withXeloda, for patients with advanced or metastatic breast cancerwhose tumors over-express protein HER2.
(Reporting by Ben Hirschler, editing by Will Waterman)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment